DPP-4抑制剂相关大疱性类天疱疮的研究进展

Research advances of DPP-4 inhibitors associated bullous pemphigoid

新型口服降糖药物二肽基肽酶-4(DPP-4)抑制剂可通过抑制DPP-4活性,提高体内内源性胰高血糖素样肽-1水平,增强肠促胰岛素作用从而维持机体的血糖稳态。除有效降低血糖水平外,它还起到保护胰岛功能,延缓疾病病程的作用。近年来,众多流行病学研究发现,DPP-4抑制剂可诱导大疱性类天疱疮(BP)的发生,在临床诊疗中,对于新发或是突然加重的BP患者,应警惕药物诱发的可能性。通过对DPP-4抑制剂、BP诊断及机制、DPP-4抑制剂相关BP的免疫特征及发病机制等方面展开综述,旨在为这类患者的诊疗提供理论性依据。

DPP-4 inhibitors,a novel oral hypoglycemic drug,can enhance endogenous glucagon-like peptide-1 level and enhance incretin action to maintain blood glucose homeostasis by inhibiting DPP-4 enzyme activity.In addition to effectively lowering blood glucose level,it also plays a role in protecting pancreatic islets and delaying the course of disease.In recent years,a number of epidemiological studies have found that DPP-4 inhibitors can induce the occurrence of bullous pemphigoid(BP).In clinical diagnosis and treatment,the possibility of drug induction should be vigilant for patients with new or suddenly aggravated BP.DPP-4 inhibitors,diagnosis and mechanism of BP,immune characteristics and pathogenesis of DPP-4 inhibitor-associated BP are reviewed,in order to provide theoretical basis for the diagnosis and treatment of such patients.